These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 1579089)

  • 1. [Cardiopulmonary effects of prostaglandin E1. Aspects of drug safety].
    Heidrich H; Breddin HK; Rudofsky G; Scheffler P
    Med Klin (Munich); 1992 Mar; 87(3):123-30. PubMed ID: 1579089
    [No Abstract]   [Full Text] [Related]  

  • 2. [Risk-benefit analysis of intra-arterial and intravenous PGE1 infusions in peripheral arterial occlusive disorders].
    Heidrich H
    Vasa Suppl; 1991; 33():346-7. PubMed ID: 1788752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effects of prostaglandin El on hemodynamics and metabolism of the extremities in healthy humans and patients with stage III and IV arterial occlusive disease].
    Rexroth W; Amendt K; Römmele U; Stein U; Wagner E; Hild R
    Vasa; 1985; 14(3):220-4. PubMed ID: 4050061
    [No Abstract]   [Full Text] [Related]  

  • 4. [Duplex ultrasound measurement of hemodynamic parameters at rest and following arterial stenosis: effect of intra-arterial infusion therapy with prostaglandin E1].
    Ranke C; Creutzig A; Alexander K
    Vasa Suppl; 1989; 27():353-5. PubMed ID: 2696104
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical application of prostaglandin E1 in cases of occlusive arterial disease.
    Mishima Y
    Adv Prostaglandin Thromboxane Leukot Res; 1985; 15():547-8. PubMed ID: 2936166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Randomized study comparing the clinical effectiveness of intravenous prostaglandin E1 and intravenous pentoxifylline in patients with Fontaine stage IIb arterial occlusive disease].
    Hepp W; von Bary S; Corovic D; Diehm C; Mühe E; Rudofsky G; Scheffler P; Trübestein G; Vogelpohl M
    Vasa Suppl; 1991; 33():348-9. PubMed ID: 1788753
    [No Abstract]   [Full Text] [Related]  

  • 7. [The use of Vasaprostan (prostaglandin E1) in treating patients with obliterating arterial diseases of the lower extremities].
    Lebedev LV; Afonin DN
    Vestn Khir Im I I Grek; 1993; 150(5-6):153-7. PubMed ID: 8091569
    [No Abstract]   [Full Text] [Related]  

  • 8. [Alprostadil combined with antithrombotic drugs. Effects on hemorrhage time].
    Minciotti A; Goracci S; Nenci GG
    Minerva Cardioangiol; 1999 Dec; 47(12):651. PubMed ID: 10670245
    [No Abstract]   [Full Text] [Related]  

  • 9. [Prostaglandin E1 between pathomechanism and therapy].
    Sinzinger H; Peskar BA
    Wien Klin Wochenschr; 1988 Jul; 100(14):469-70. PubMed ID: 3062903
    [No Abstract]   [Full Text] [Related]  

  • 10. Prostaglandin E1 in chronic arterial disease: a multicenter study.
    Trübestein G; Diehm C; Gruss JD; Horsch S
    Prog Clin Biol Res; 1987; 242():445-51. PubMed ID: 3313418
    [No Abstract]   [Full Text] [Related]  

  • 11. [New, in Austria registered specialty drugs. Prostavasin (alprostadil)].
    Oberhuber G
    Wien Klin Wochenschr; 1992; 104(5):137-41. PubMed ID: 1574906
    [No Abstract]   [Full Text] [Related]  

  • 12. [Prostaglandin therapy in arterial occlusive disease].
    Kruse HJ; Schellong S
    Dtsch Med Wochenschr; 2001 Mar; 126(11):315-6. PubMed ID: 11296573
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of prostaglandin E1 upon collateral vessels in peripheral occlusive arterial disease.
    Rudofsky G; Gerngross U
    Prog Clin Biol Res; 1989; 301():407-9. PubMed ID: 2798455
    [No Abstract]   [Full Text] [Related]  

  • 14. Prostaglandin E1 : electrophysiological safety in patients with congestive heart failure and peripheral arterial occlusive disease. The Alprostadil Investigators.
    Somberg JC; Yelamanchi V; Molnar J; Aschermann M; Bernink PJ; Caspi A; Marmor A; Rabinowitz B; Reisin L; Ruzyllo W
    Am J Ther; 1997; 4(11-12):401-4. PubMed ID: 10423637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of prostaglandin E1 for the treatment of peripheral arterial occlusive disease in patients with congestive heart failure. The Alprostadil Investigators.
    Reisin L; Marmor A; Rabinowitz B; Bernink PJ; Caspi A; Ruzyllo W; Borer JS
    Am J Ther; 1997; 4(11-12):365-74. PubMed ID: 10423632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iontophoretic administration of prostaglandin E1 in peripheral arterial occlusive disease.
    Sakurai T; Yamamura K
    Ann Pharmacother; 2003 May; 37(5):747. PubMed ID: 12708957
    [No Abstract]   [Full Text] [Related]  

  • 17. Prostaglandin E1 in heart failure: the Vienna experience.
    Pacher R; Stanek B
    Wien Klin Wochenschr; 1996; 108(16):491-5. PubMed ID: 8840496
    [No Abstract]   [Full Text] [Related]  

  • 18. Intraarterial perfusion of prostaglandin E1 after lumbar sympathectomy or reconstruction on femoropopliteal segment.
    Davidovic LB; Vranes MR; Lotina SI; Cernak IF; Velimirovic DB; Stojanov PL; Sindjelic RP; Sagic DZ; Cinara IS
    Int Angiol; 1991; 10(3):178-81. PubMed ID: 1765722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and haemostatic effects of intravenous prostaglandin E1 therapy in patients with peripheral arterial occlusive disease.
    Trifiletti A; Scamardi R; Pizzoleo MA; Sottilotta G; Soraci S; Attinà A; Bagnato L; Barbera N
    Panminerva Med; 1999 Mar; 41(1):15-7. PubMed ID: 10230250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of prostaglandin E1 on function and deformability of neutrophilic granulocytes in patients with stage IV peripheral arterial occlusive disease].
    Neumann FJ; Diehm C; Müller-Bühl U; Weiss T; Zimmermann R; Tillmanns H; Kübler W
    Vasa Suppl; 1989; 27():40-1. PubMed ID: 2623539
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.